Want to see IART full AI Analyst Report?
Top Page
Integra Lifesciences
(NASDAQ:IART)
Select Model
Select Model
Rating:49Neutral
Price Target:
$16.50
▼(-16.62% Downside)
Action:Reiterated
Date:07/30/26
The score is held down primarily by weak financial performance (losses, volatile profitability, elevated leverage and inconsistent free cash flow) and only mixed technical setup (below 20/50-day averages). The earnings call was a meaningful positive with reaffirmed guidance, margin and cash flow improvement, and ongoing deleveraging, but valuation remains challenged due to a negative P/E and no dividend yield provided.
Positive Factors
Diversified Specialty Portfolio
Integra's mix across neurosurgery, implants and reconstructive products provides recurring procedure-linked consumable demand and exposure to higher-growth neuro tools (CUSA, Certas Plus). This diversification supports steadier revenue over months as different end markets recover unevenly.
Negative Factors
Elevated Leverage
High net debt (~$1.6B) and multi-turn leverage reduce balance-sheet flexibility and increase refinancing and interest-rate risk. Sustained earnings weakness could constrain investment, require aggressive cash conversion, and amplify vulnerability to higher interest costs during planned H2 refinancing.
Read all positive and negative factors
Positive Factors
Negative Factors
Diversified Specialty Portfolio
Integra's mix across neurosurgery, implants and reconstructive products provides recurring procedure-linked consumable demand and exposure to higher-growth neuro tools (CUSA, Certas Plus). This diversification supports steadier revenue over months as different end markets recover unevenly.
Read all positive factors
Integra Lifesciences (IART) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.29B
Dividend YieldN/A
Average Volume (3M)682.69K
Price to Earnings (P/E)―
Beta (1Y)1.77
Revenue Growth1.60%
EPS Growth98.56%
CountryUS
Employees4,427
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.09
Shares Outstanding77,772,510
10 Day Avg. Volume691,147
30 Day Avg. Volume682,692
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.91
Price to Sales (P/S)0.58
P/FCF Ratio-21.06
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$20.71Price Target Upside4.67% Upside
Rating ConsensusHold
Number of Analyst Covering9
EPS Forecast (FY)2.45
Revenue Forecast (FY)$1.68B
Integra Lifesciences Business Overview & Revenue Model
Company Description
Integra LifeSciences Holdings Corporation is a medical technology company focused on the creation, production, and global distribution of advanced surgical implants and instruments. These products are utilized across various medical fields, includ...
How the Company Makes Money
Integra makes money primarily by selling medical devices, implants, and surgical instruments to healthcare providers (e.g., hospitals and surgical centers) through a mix of direct sales and distribution channels, with revenue recognized when produ...
Integra Lifesciences Earnings Call Summary
Earnings Call Date:Jul 29, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 04, 2026
Earnings Call Sentiment Positive
The call emphasized steady, constructive progress: revenue and EPS tracked to guidance with meaningful margin expansion, improved operating cash flow, successful product relaunch momentum (PriMatrix) and a key operational milestone with Braintree restarting to enable the SurgiMend relaunch. Management reaffirmed full-year organic growth and adjusted EPS guidance while outlining cost savings and deleveraging priorities. Offsetting positives are softness in tissue reconstruction and ENT, competitive pressure on MicroMatrix, continued high net debt and the timing risk tied to FDA inspections and refinancing-related interest expense. Overall the positives (execution, margin/cash improvement, product relaunches and supply recovery) substantially outweigh the headwinds, though timing and leverage risks remain.)Positive Updates
Revenue and EPS Delivery
Q2 revenue of $419.0M, up $27M sequentially; reported revenue growth +0.8% YoY and organic growth +0.7% YoY. Adjusted EPS $0.56, up 24% YoY and above the high end of guidance (beat consensus by ~$0.08). Tariff favorability contributed ~$0.05 per share in the quarter.
Negative Updates
Tissue Reconstruction Revenue Decline
Tissue Reconstruction revenues $109.5M, down 1.9% on a reported basis and down 2.0% organically versus prior year. Integra Skin was down YoY (though sequentially up) and MicroMatrix declined, leaving wound reconstruction ~flat in H1 2026.
Read all updates
Q2-2026 Updates
Positive
Negative
Revenue and EPS Delivery
Q2 revenue of $419.0M, up $27M sequentially; reported revenue growth +0.8% YoY and organic growth +0.7% YoY. Adjusted EPS $0.56, up 24% YoY and above the high end of guidance (beat consensus by ~$0.08). Tariff favorability contributed ~$0.05 per share in the quarter.
Read all positive updates
Company Guidance
Management reaffirmed full-year 2026 adjusted EPS of $2.40–$2.50 and organic revenue growth of 0.8%–3.3% while updating reported revenue to $1.654–$1.695 billion (reported growth 1.1%–3.7%) due to FX; Q3 revenue is guided to $410–$425 million (reported growth 2.0%–5.7%, organic 1.9%–5.7%) with Q3 adjusted EPS of $0.53–$0.61. Q2 results included adjusted EPS $0.56 (up 24% YoY; $0.04 above the guidance range and $0.08 above the midpoint), revenue $419M, gross margin 61.3% (≈+60 bps YoY), adjusted EBITDA margin 18.7% (≈+160 bps YoY), operating cash flow $22.8M in the quarter ($35M H1), free cash flow $10.5M (24% conversion), capex $12.3M in Q2, net debt $1.6B and total leverage 4.1x (down from 4.5x). They expect to approach the upper end of target leverage (2.5x–3.5x) by year-end, plan to refinance bank debt in H2 2026 (may raise interest expense but expect tariff favorability—Q2 tariff benefit ≈$0.05 and estimated full‑year tariff exposure ≈$0.10—to offset it), and reiterated ~$25–$30M of 2026 cost savings (with an incremental $10–$15M annualized in 2027) and an anticipated ≈$150M improvement in operating cash flow for the year (including ≈$60M lower cash outlays related to EU MDR and Braintree).Integra Lifesciences Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
41
Neutral
Cash Flow
46
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.65B | 1.64B | 1.61B | 1.54B | 1.56B | 1.54B |
| Gross Profit | 885.45M | 845.23M | 882.06M | 884.74M | 970.31M | 944.64M |
| EBITDA | 210.66M | -326.20M | 193.29M | 255.96M | 384.60M | 366.33M |
| Net Income | -7.24M | -516.47M | -6.94M | 67.74M | 180.55M | 169.07M |
Balance Sheet | ||||||
| Total Assets | 3.59B | 3.60B | 4.04B | 3.78B | 3.89B | 3.78B |
| Cash, Cash Equivalents and Short-Term Investments | 274.08M | 263.74M | 273.57M | 309.10M | 456.66M | 513.45M |
| Total Debt | 2.04B | 2.03B | 1.98B | 1.68B | 1.63B | 1.67B |
| Total Liabilities | 2.54B | 2.56B | 2.49B | 2.19B | 2.09B | 2.10B |
| Stockholders Equity | 1.05B | 1.04B | 1.55B | 1.59B | 1.80B | 1.68B |
Cash Flow | ||||||
| Free Cash Flow | 38.76M | -45.25M | 24.96M | 73.09M | 217.38M | 264.35M |
| Operating Cash Flow | 85.33M | 50.38M | 129.38M | 139.96M | 264.47M | 312.43M |
| Investing Cash Flow | -108.63M | -108.06M | -390.81M | -94.18M | -58.58M | -161.44M |
| Financing Cash Flow | 20.82M | 28.34M | 237.86M | -229.93M | -251.95M | -98.23M |
Integra Lifesciences Technical Analysis
Positive
19.79
Price Trends
17.65
Positive
14.29
Positive
13.34
Positive
Market Momentum
0.03
Positive
48.88
Neutral
26.44
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IART, the sentiment is Positive. The current price of 19.79 is above the 20-day moving average (MA) of 18.46, above the 50-day MA of 17.65, and above the 200-day MA of 13.34, indicating a neutral trend. The MACD of 0.03 indicates Positive momentum. The RSI at 48.88 is Neutral, neither overbought nor oversold. The STOCH value of 26.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IART.
Integra Lifesciences Risk Analysis
Integra Lifesciences disclosed 31 risk factors in its most recent earnings report. Integra Lifesciences reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Integra Lifesciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | $1.97B | 28.63 | 16.61% | ― | 11.19% | 7.61% | |
77 Outperform | $1.10B | 31.11 | 16.27% | ― | 1.52% | ― | |
74 Outperform | $2.27B | -62.55 | -17.88% | ― | 23.57% | -543.50% | |
67 Neutral | $1.39B | 24.99 | 5.51% | 2.02% | 3.86% | -48.06% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $1.29B | -180.59 | -0.69% | ― | 1.60% | 98.56% | |
49 Neutral | $476.98M | -7.84 | -13.44% | ― | 2.59% | 59.39% |
* Healthcare Sector Average
IART
Integra Lifesciences
16.65
4.09
32.56%
CNMD
Conmed
46.30
-6.98
-13.10%
OFIX
Orthofix Medical
11.80
0.95
8.76%
UFPT
Ufp Technologies
254.78
28.51
12.60%
AXGN
AxoGen
42.21
29.66
236.33%
BVS
Bioventus
13.17
6.85
108.39%
Integra Lifesciences Corporate Events
Business Operations and StrategyShareholder Meetings
Integra Lifesciences Shareholders Approve Expanded Equity Incentive Plan
Positive
May 8, 2026
Integra LifeSciences held its 2026 Annual Meeting of Stockholders on May 7, 2026, where shareholders approved Amendment No. 3 to the company’s Fifth Amended and Restated 2003 Equity Incentive Plan, adding 3,550,000 shares of common stock for...
Business Operations and StrategyExecutive/Board Changes
Integra LifeSciences Names Stuart Essig President and CEO
Positive
May 5, 2026
On May 5, 2026, Integra LifeSciences announced that long-time board chair Stuart Essig has been appointed president and chief executive officer, effective May 1, 2026, succeeding Mojdeh Poul, who departed on April 30, 2026, and that he will also r...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.